Skip to main content
. 2017 Oct 23;37(6):756–767. doi: 10.1038/onc.2017.365

Figure 6.

Figure 6

Protective role of BDNF against B-CLL apoptosis. (a) BDNF concentration, quantified by ELISA, in B-CLL patient plasma (n=17, gray boxes) in comparison with healthy donor plasma (n=9, white boxes). (b) Quantitative analysis of BDNF mRNA level in normal B (n=15) and B-CLL (n=30) cells. Data are expressed as mean fold change in expression (±s.e.m.) vs normal B cells. (c) Representative western blot analysis of pro-BDNF and mature BDNF (mBDNF) expression in normal B and B-CLL supernatants after 24 h of culture post-isolation. (d) Western blot analysis of P-Src, Bcl-xL and Bcl-2 in B-CLL cell lysates from two patients after addition of BDNF (100 ng/ml) for 24 h. (e, f) Expression levels of p-Src (e), Bcl-xL and Bcl-2 (f) represented as, respectively, the ratio of phosphorylated Src vs pan-Src protein and the ratios of Bcl-xL and Bcl-2 to actin (B-CLL, n=3). Values are means±s.e.m. of three independent experiments, in a.u. (g, h) Apoptotic ratio, assessed by cell death ELISA, in B-CLL cells cultured with or without 100 ng/ml BDNF for 24 h (B-CLL, n=4) in the presence or absence of siRNA against NTSR2 or control siRNA. Values are the mean ratio of apoptotic cells (±s.e.m.) from four independent experiments. Significant P-values are indicated in the graphs *P<0.05, **P<0.01, ***P<0.001.